SeekingAlpha · Sep 14, 2026
The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell
Moderna (MRNA) and MRNY are rated Sell on stretched valuation after melanoma Phase 3 news.
MR
AMEX · MRNY
YieldMax MRNA Option Income Strategy ETF
Public company research
$46.08
Up+$0.49 (+1.06%)
Updated Oct 22, 2026, 1:20 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 78.91M
- P/E ratio
- —
- Dividend yield
- 5.52%
- 52-week range
- $14.01 – $46.22
- Volume
- 385.22K
- Avg. volume
- 173.67K
Price performance · MRNY
MRNY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
MRNY closed at $46.08 after 20 trading sessions, up 18.03% for the selected period.
- Last close
- $46.08
- Period change
- +18.03%
- Period low
- $38.69
- Period high
- $46.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $43.48 | $46.22 | $41.89 | $46.08 | 385.22K |
| Oct 19, 2026 | $41.84 | $45.115 | $41.75 | $43.53 | 298.23K |
| Oct 16, 2026 | $44.24 | $44.37 | $40.39 | $42.00 | 681.52K |
| Oct 15, 2026 | $42.57 | $45.3892 | $41.59 | $44.24 | 372.34K |
| Oct 14, 2026 | $42.48 | $43.9399 | $41.37 | $43.73 | 478.37K |
| Oct 13, 2026 | $40.80 | $42.46 | $40.22 | $42.21 | 204.41K |
| Oct 12, 2026 | $43.47 | $43.84 | $41.295 | $41.76 | 325.84K |
| Oct 9, 2026 | $39.80 | $43.73 | $39.63 | $43.63 | 539.85K |
| Oct 8, 2026 | $39.47 | $39.855 | $38.90 | $39.67 | 136.09K |
| Oct 7, 2026 | $38.06 | $40.25 | $37.93 | $40.20 | 315.33K |
| Oct 6, 2026 | $40.88 | $42.5645 | $38.635 | $38.69 | 367.58K |
| Oct 5, 2026 | $39.32 | $41.5287 | $38.40 | $41.19 | 327.77K |
| Oct 2, 2026 | $39.11 | $39.53 | $37.67 | $39.10 | 185.83K |
| Oct 1, 2026 | $38.03 | $40.54 | $38.03 | $38.86 | 182.21K |
| Sep 30, 2026 | $39.07 | $40.505 | $38.65 | $40.21 | 517.13K |
| Sep 29, 2026 | $40.77 | $42.6326 | $40.43 | $41.81 | 277.41K |
| Sep 28, 2026 | $40.27 | $41.0703 | $39.21 | $40.61 | 395.27K |
| Sep 25, 2026 | $40.13 | $41.55 | $39.78 | $40.77 | 240.29K |
| Sep 24, 2026 | $37.50 | $40.42 | $37.50 | $40.42 | 278.27K |
| Sep 23, 2026 | $38.62 | $40.4699 | $38.38 | $39.04 | 581.51K |
Latest MRNY news
The latest Smart Investors Daily articles mentioning MRNY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MRNY research
Overview
Company profile and research snapshot.
Company profile
The fund advisor will employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will take temporary defensive positions during such periods. The fund is non-diversified.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 21, 2026
MRNY: Options Income Strategy For Indirect Moderna Exposure
YieldMax MRNY ETF: weekly income via Moderna covered calls, 84.6% yield and key risks like capped upside, thin liquidity & NAV erosion. Learn more about MRNY ETF here.
SeekingAlpha · Jun 26, 2026
MRNY: The Yield Is Too Aggressive For Long-Term Sustainability
SeekingAlpha · Jan 22, 2026
MRNY: Jumping On Big Moderna Move
YieldMax MRNA Option Income Strategy ETF's distributions have increased alongside MRNA's share price resurgence. See more on MRNY ETF here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
